Neurology & Psychiatry · LP-158
Sodium valproate Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-158Neurology & Psychiatry
- Generic identity
- Sodium valproateTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-158
- Generic ingredient
- Sodium valproate
- Dosage form
- Tablet
- Proposed strength
- 200 mg; 500 mg
- Proposed pack
- Blister/bottle
- Portfolio category
- Neurology & Psychiatry
About Sodium valproate
Sodium valproate is an antiseizure medicine with additional uses in some jurisdictions and clinical settings. It affects several mechanisms involved in neuronal excitability. Its benefit-risk assessment includes major reproductive safety considerations as well as the neurological diagnosis. Tablet strengths alone do not establish the release formulation, and valproate-related products should not be substituted simply because their names appear similar.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinical use requires an appropriate specialist-led assessment of seizure type or other supported indication, previous response and available alternatives. The formulation and release characteristics influence continuity of treatment. Current pregnancy-prevention requirements and reproductive counselling must be checked in the jurisdiction of use, including advice relevant to male patients where applicable. This catalogue does not define an eligibility programme, endorse use in pregnancy or supply a treatment schedule.
Important safety considerations
Valproate can cause serious birth defects and neurodevelopmental harm following pregnancy exposure. Liver injury, pancreatitis, blood-cell abnormalities and hyperammonaemia are further major risks. Severe abdominal pain, persistent vomiting, jaundice or unusual confusion require prompt assessment. Weight gain, tremor and sedation can occur. Review liver disease, metabolic disorders, pregnancy potential and interactions. Patients should seek urgent specialist advice about pregnancy concerns and should not abruptly stop antiseizure treatment without medical direction.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source gives tablet strengths without a release designation. Conventional, enteric-coated and prolonged-release valproate products require separate identification. Exact chemical form, equivalence conventions and packaging must be confirmed from the product dossier.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm diagnosis, formulation, reproductive safety requirements, relevant laboratory monitoring and interaction risks. Use current specialist guidance and the exact local product information.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Sodium valproate
- Dosage form / presentation
- Tablet
- Catalogue strength
- 200 mg; 500 mg
- Catalogue pack
- Blister/bottle
- Portfolio category
- Neurology & Psychiatry
Layer 02
Unresolved product-specific fields
- The catalogue states sodium valproate tablets at 200 mg and 500 mg but does not state conventional, enteric/delayed-release or prolonged-release character. Release type must remain unknown.
- Do not infer equivalence to valproic acid, divalproex or another valproate presentation solely from shared valproate pharmacology.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Valproic Acid — formulation contextgovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-158, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-158.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.